Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced the publication of results from the dose escalation part of the Phase 1 clinical trial in the journal Lancet Oncology. The publication, titled “Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial” was authored by the clinical investigators of the first-in-man Phase 1 study as well as members of Curis’ clinical and scientific teams. The publication is also accompanied by an independent commentary in the journal titled “Dual inhibition of oncogenic targets for B-cell malignancies” by Paul G. Richardson, M.D., R.J. Corman Professor of Medicine at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute.

“The data from the Phase 1 monotherapy trial for CUDC-907, especially in heavily pretreated patients with relapsed/ refractory DLBCL are very encouraging and we look forward to data emerging from the current Phase 2 trial in patients with MYC-altered DLBCL,” said Dr. Anas Younes, M.D., Chief of the Lymphoma Service of the Memorial Sloan Kettering Cancer Center in New York City, the Principal Investigator of the Phase 1 trial and the publication’s senior author.

Based on the clinical activity observed in patients with relapsed/ refractory-DLBCL, particularly those with cancers harboring MYC alterations, Curis has initiated a Phase 2 trial to evaluate CUDC-907 in patients with MYC-altered RR-DLBCL. (Original Source)

Shares of Curis closed last Friday at $1.63, up $0.02 or 1.24%. CRIS has a 1-year high of $3.75 and a 1-year low of $1.25. The stock’s 50-day moving average is $1.56 and its 200-day moving average is $2.09.

On the ratings front, Roth Capital analyst Joseph Pantginis maintained a Buy rating on CRIS, with a price target of $5, in a report issued on February 29. The current price target represents a potential upside of 206.7% from where the stock is currently trading. According to, Pantginis has a yearly average return of -4.1%, a 37.6% success rate, and is ranked #3636 out of 3775 analysts.

Curis, Inc. is a biotechnology company, which is to develop and commercialize innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. The company conducts research programs both internally and through strategic collaborations. Curis was founded on February 14, 2000 and is headquartered in Lexington, MA.